Author:
Ahmed Saeed,Faruqui Zeeshan,Poddar Karuna,Bhivandkar Siddhi,Suzuki Joji
Abstract
Buprenorphine, a partial opioid agonist, is a Food and Drug Administration-approved medication for the treatment of opioid use disorder (OUD). However, due to its high binding affinity, precipitated withdrawal may occur if initiated in the presence of other opioids. The growing literature demonstrates promise for alternative induction model of low-dose initiation of buprenorphine for the treatment of OUD, specifically targeting patients averse to withdrawal or using fentanyl. In this case series, we present four clinical cases of outpatient inductions, in which three out of four successfully transitioned from fentanyl to buprenorphine, and one patient transitioned from methadone to buprenorphine using a low-dose induction method.
Publisher
Weston Medical Publishing
Subject
Anesthesiology and Pain Medicine,Pharmacology (medical),General Medicine
Reference28 articles.
1. National Center for Health Statistics: Drug overdose deaths in the US top 100 annually, GA: US Department of Health and Human Services, CDC. 2021. Available at https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2021/20210714.htm. Accessed July 2021.
2. Florence C, Luo F, Rice K: The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug Alcohol Depend. 2021; 218: 108350.
3. US Food and Drug Administration: Information about medication-assisted treatment (MAT). 2019
4. 14: 758-768. Available at https://www.fda.gov/drugs/information-drugclass/information-about-medication-assisted-treatment-mat. Accessed June 30, 2023.
5. Sordo L, Barrio G, Bravo MJ, et al.: Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ. 2017; 357: j1550. DOI: 10.1136/bmj.j1550.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Buprenorphine/naloxone/fentanyl;Reactions Weekly;2024-01-13